Keystone Nano, Inc.

12/03/2018

KEYSTONE NANO ANNOUNCES THE US FDA HAS AWARDED ORPHAN DRUG DESIGNATION FOR USE OF CERAMIDE FOR THE TREATMENT OF PANCREATIC CANCER

At Keystone Nano, we are solving big problems with nano solutions.  We are testing nanoscale therapies in cancer clinics around the United States.

11/25/2017

The Promise of Nanomedicine

https://www.laboratoryequipment.com/article/2017/11/promise-nanomedicine

11/03/2017

STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia

The mechanism by which anticancer agent C6-ceramide kills chronic lymphocytic leukemia cells has been illuminated by a team in the USA. Previous studies had shown that C6-ceramide encapsulated in nanoliposomes (CNL) selectively kills cancer cells, and CNL is currently undergoing clinical trials f...

10/05/2017

Check out the latest interview with James Adair!

James Adair, PhDPenn State University

10/03/2017

The use of nanoparticulates to treat breast cancer -

Nanomedicine (Lond). 2017 Oct;12(19):2367-2388. doi: 10.2217/nnm-2017-0202. Epub 2017 Sep 4.

09/21/2017

Researchers at Penn State say they've developed a therapy to treat some of the most resistant cancers without damaging any healthy cells.

08/29/2017

University of Virginia Cancer Center and Keystone Nano, Inc. announce that clinical testing has been initiated at UVA on a new potential cancer therapy. The study is a Phase I clinical trial to assess Ceramide NanoLiposome in the treatment of solid tumors.

http://bit.ly/2wgHSJO

University of Virginia Cancer Center and Keystone Nano, Inc. announce that clinical testing has been initiated at UVA on a new potential cancer therapy. The study is a Phase I clinical trial to assess Ceramide NanoLiposome in the treatment of solid tumors.

07/13/2017

Check out pictures from the Life Sciences Pennsylvania event held June 27th announcing the new space available for Pennsylvania life sciences companies!

07/03/2017

Investigational cancer compound receives FDA approval to begin human trials: http://bit.ly/2uDyvQG

An investigational compound developed by Penn State researchers that targets and destroys cancer cells while leaving healthy cells unharmed has been approved for phase one clinical human trials by the U.S. Food and Drug Administration (FDA).

04/18/2017

Keystone Nano Announces Progress On RNA Delivery

STATE COLLEGE, Pa., April 11, 2017 /PRNewswire/ -- Keystone Nano, Inc. (KN), a clinical stage biopharmaceutical...

04/17/2017

Jeff Davidson, CEO of Keystone Nano, will be speaking at Penn State Universities startup week. Wednesday, April 19, at 8 am in 175 Williard Building, University Park, PA.

https://startupweek.psu.edu/speakers